Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
Award amount
$1,999,257Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHARMAIN CORPORATION
- Proposal award date
- 2017-08-10
- Contract end date
- 2020-03-31
- UEI
- G1NAHNEAVKK9
- Solicitation number
- PAR14-088
- Topic code
- NHLBI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Subcutaneous Drug Development for Portal Hypertension Ascites
- Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
- CMC of Peptide Formulation for the Treatment of ARDS
- CMC of Peptide Formulation for the Treatment of ARDS
- Subcutaneous Drug Development for Portal Hypertension Ascites
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
21 SBIR/STTR records share this UEI (2004–2024). Reported award amounts total $21,739,117. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services